Nanobac Pharmaceuticals Changes Name to Nanobac Life Sciences

Nanobac Pharmaceuticals, Inc. re-named the company Nanobac Life Sciences, Inc. The revised name reflects Nanobac’s mission to fully exploit its leading portfolio of Nanobacteria intellectual property to develop diagnostics and therapeutics to detect and treat Nanobacterial infections, as well as continue research into the role of Nanobacteria in the formation of disease-causing calcified plaque in the circulatory system and vital organs.

"Currently, we are researching Nanobacterial infection as a risk factor for the development of atherosclerosis and coronary heart disease. We are also developing an antibody and antigen serum test for Nanobacterial infection for which we will seek FDA marketing approval, and we plan to further leverage our patent estate through the development of therapeutics and additional diagnostic tests," said Alex Edwards, Nanobac’s CEO and President.

“There are several other potential applications in the Bio-medical and Bio-industrial areas, such as sterilization of vaccines, growth mediums and equipment, being considered. In light of the breadth of potential applications that we seek to develop, it was proper to change the name of the company,” Mr. Edwards concluded.

Nanobac, through its wholly owned subsidiary, Nanobac OY, owns patents pertaining to culture and detection methodologies as well as methods for eradication of Nanobacteria. These patents apply to In Vivo, In Vitro and Industrial applications. Nanobacteria have been associated as one of the causes of pathological calcification (implicated in Atherocslerosis and other stones and cysts) and have also been cultured out of solid tumours.

Nanobac is currently finishing statistical analysis of the performance of its serum based Biomarker for the detection of both active and latent Nanobacterial infection.